Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03337542 · ClinicalTrials.gov registry record · Phase 3
AR101 Real-World Open-Label Extension Study
A Phase 3 study of Peanut Allergy, sponsored by Aimmune Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 243
- Enrollment target
- 20
- Study locations
NCT03337542 is a Phase 3 study of Peanut Allergy that has completed, run by Aimmune Therapeutics. The registered enrollment target is 243 participants, above the 196-participant average among 13 other Peanut Allergy trials with a reported enrollment target (24% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT03337542, a Phase 3 study of Peanut Allergy, has completed, sponsored by Aimmune Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 243 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.
Conditions Studied
Interventions
- BIOLOGICAL AR101
Study Locations (20)
California
- Jonathan Corren, M.D., Inc. - Los Angeles
- Allergy & Asthma Associates of Southern California - Mission Viejo
- Sean N. Parker Center for Allergy Research at Stanford University - Packard-El Camino Hospital - Mountain View
- Peninsula Research Associates - Rolling Hills Estates
- Allergy & Asthma Medical Group and Research Center - San Diego
- Rady Children's Hospital, Div. Allergy & Immunology, UC San Diego - San Diego
- UCSF, Benioff Children's Hospital - Allergy and Immunology - San Francisco
- Allergy & Asthma Associates of Santa Clara Valley Research Center - San Jose
- UCLA Medical Center, Santa Monica - Santa Monica
- Bay Area Allergy - Walnut Creek
Colorado
- Children's Hospital Colorado - Aurora
- Asthma & Allergy Associates - Colorado Springs
- National Jewish Health - Denver
- Colorado Allergy & Asthma Centers, P.C. - Denver
Arizona
- Medical Research of Arizona - Scottsdale
- Banner University of Arizona Medical Center - Tucson
Alabama
- Clinical Research Center of Alabama - Birmingham
Arkansas
- Arkansas Children's Hospital - Little Rock
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- Sher Allergy Specialists - Center for Cough - Largo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2017-10-18 |
| Est. Completion | 2019-09-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03337542
The ClinicalTrials.gov registry entry for NCT03337542 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 196-participant average among 13 other Peanut Allergy trials with a reported enrollment target (24% higher). The listed sponsor is Aimmune Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peanut Allergy appearing as the primary indexed condition, and to 1 intervention - of which AR101 is the first listed.
NCT03337542 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Colorado, Arizona.
Frequently Asked Questions
What is clinical trial NCT03337542 about?
NCT03337542 is a clinical study titled "AR101 Real-World Open-Label Extension Study". This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.
What is the current status of trial NCT03337542?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 243 participants. The study started on 2017-10-18. Estimated completion is 2019-09-20.
What conditions does trial NCT03337542 study?
This clinical trial studies the following conditions: Peanut Allergy.
What interventions are being tested in trial NCT03337542?
The interventions under investigation include: AR101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03337542?
This trial is sponsored by Aimmune Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03337542 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peanut Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
RECRUITING · Phase 3
-
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
COMPLETED · Phase 3
-
Safety Study of Viaskin Peanut to Treat Peanut Allergy
COMPLETED · Phase 3
-
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)
COMPLETED · Phase 3
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.